This is a study to determine what Human Papillomavirus HIV seropositive women in Botswana, South Africa and Brasil have been exposed to during their life. The Human Papillomavirus causes cervical cancer. Different types are more likely to lead to cancer than other types. A vaccine has been made to fight infection against HPV 16 and 18 which has been shown to cause cervical cancer in America and Europe. What HPV type cause cancer in other countries is not as well studied.

Hypothesis HPV serology will demonstrate that exposure to each HPV type in Gardisil (6,11,16,18) will be <50% in HIV seropositive women in resource limited countries.

HIV seropositive women from an HIV Antiretroviral therapy clinic in Johannesburg South Africa

2

A cohort of HIV seropositive women from Gabarone Botswana

3

A cohort of HIV seropositive women from Rio De Janeiro Brasil

Detailed Description:

Plasma from HIV seropositive women will be taken and sent to MERCK in the USA to evaluate what the antibody titers of HPV 6,11,16 and 18. .

Eligibility

Ages Eligible for Study:

18 Years and older

Genders Eligible for Study:

Female

Accepts Healthy Volunteers:

No

Sampling Method:

Non-Probability Sample

Study Population

HIV seropositive women from South Africa, Botswana, and Brasil

Criteria

Inclusion Criteria:

HIV seropositive women 18 years of age and older Consent signed per local IRB requirement

Exclusion Criteria:

Can not give blood

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00840905

Locations

Botswana

Shahin Lockman

Habarone, Botswana

Brazil

Fundacao Oswaldo Cruz

Rio De Janeiro, Brazil

South Africa

University of Witwatersrand/Helen Joseph Hospital

Johannesburg, South Africa

Sponsors and Collaborators

Cynthia S Firnhaber

Merck Sharp & Dohme Corp.

Investigators

Principal Investigator:

Cynthia S Firnhaber, MD

Clinical HIV Research Unit University of Witwatersrand

More Information

No publications provided

Responsible Party:

Cynthia S Firnhaber, Associate Professor of Medicine, University of Witwatersrand, South Africa